<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507569</url>
  </required_header>
  <id_info>
    <org_study_id>BP40257</org_study_id>
    <nct_id>NCT03507569</nct_id>
  </id_info>
  <brief_title>Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513</brief_title>
  <official_title>A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with
      the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773
      in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">October 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773</measure>
    <time_frame>Baseline up to 48 hours (hrs)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of RO701773</measure>
    <time_frame>Baseline up to 48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Screening to end of study (up to 8 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>RO7017773</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7017773</intervention_name>
    <description>RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.</description>
    <arm_group_label>RO7017773</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C] Ro15-4513</intervention_name>
    <description>At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer [11C]Ro15-4513.</description>
    <arm_group_label>RO7017773</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy (absence of evidence of any active or chronic disease following a detailed
             medical and surgical history, a complete physical examination including vital signs,
             12-lead ECG, hematology, blood chemisty, serology, and urinalysis), as judged by the
             Investigator.

          -  Males and women of non-childbearing potential (WONCBP)

        Exclusion Criteria:

          -  History of convulsions (other than benign febrile convulsions of childhood) including
             epilepsy, or personal history of significant cerebral trauma or CNS infections

          -  Clinically significant abnormal finding from the MRI performed after the initial
             screening examination

          -  Abnormal blood pressure, i.e, systolic blood pressure (SBP) greater than 140 or less
             than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm
             Hg

          -  Abnormal pulse rate, resting pulse rate greater than 100 or less than 40 bpm

          -  History or presence of clinically significant ECG abnormalities before study drug
             administration or cardiovascular disease

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Positive result on hepatitis B (HBV) or hepatitis C (HCV), presence of hepatitis B
             surface antigen (HBsAg) or positive hepatitis C antibody test result at screening or
             within 3 months prior to starting study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research; Central Middlesex Hospital</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Luke</last_name>
      <phone>+44 0208 9638 709</phone>
      <email>lbenjamin@hmrlondon.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

